SEC Form 4 · accession 0001209191-16-122989
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D. Clayman
Officer — President and CEO · Director
Period of report
May 23, 2016
Accepted (ET)
May 24, 2016 · 5:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 23, 2016 | M | 10,369 | $0.1626 | A | 25,722 | D | |
| Common Stock | holding | — | — | — | 278,661 | I | By the Michael D. Clayman 2006 Revocable Trust | |
| Common Stock | holding | — | — | — | 24,600 | I | By the Michael D. Clayman Irrevocable Trust | |
| Common StockF2 | holding | — | — | — | 388,683 | I | By Versant Development Fund III, Fund |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F3 | $0.1626 | May 23, 2016 | M | 10,369 | D | — | Sep 23, 2019 | Common Stock | 10,369 | 0 | D |
Explanation of responses
- F1Includes 1,785 shares of Common Stock that were acquired by the Reporting Person on May 20, 2016 at $8.92 per share pursuant to the Issuer's Employee Stock Purchase Plan.
- F2Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
- F3The stock option is fully vested and exercisable.